Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 251

Sort by

Sort Order Select

Journal Articles

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

Songyi Park, Sang-A Kim, Ji Yun Lee, Ja Min Byun, Jeong-Ok Lee, Youngil Koh, Junshik Hong, Junglim Lee, Soo-Mee Bang, Inho Kim, Sung-Soo Yoon, Dongyeop Shin

Blood (2024) 144 (Supplement 1): 5944.

https://doi.org/10.1182/blood-2024-202293

Published: 2024

Journal Articles

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2024-199074

Published: 2024

Journal Articles

Spectrum of TP53 Mutation in Hematologic Malignancies

Seo Yoon Jang, Joowon Jang, Jee-Soo Lee, Songyi Park, Ja Min Byun, Youngil Koh, Junshik Hong, Inho Kim, Sung-Soo Yoon, Dong-Yeop Shin

Blood (2024) 144 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2024-210051

Published: 2024

Journal Articles

Distinct Factors Influence on Complete Hematological Response Maintenance in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b: From a Phase 2 Study in South Korea

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Yunsuk Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 6673.

https://doi.org/10.1182/blood-2024-206881

Published: 2024

Journal Articles

Ropeginterferon in Low-Risk Patients with Polycythemia Vera

Ji Yun Lee, Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Sang Kyun Sohn, Seug Yun Yoon, Soo-Mee Bang, Gyeong Won Lee, Chul Won Choi, Yunsuk Choi, June-Won Cheong, Young Hoon Park

Blood (2024) 144 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2024-202345

Published: 2024

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett

Blood (2024) 144 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2024-197902

Published: 2024

Journal Articles

First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2024-204614

Published: 2024

Journal Articles

Refining Symptom Response Criteria in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 6642.

https://doi.org/10.1182/blood-2024-206509

Published: 2024

Journal Articles

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Blood (2024) 144 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2024-194612

Published: 2024

Journal Articles

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Blood (2024) 144 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2024-205164

Published: 2024

Journal Articles

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Blood (2024) 144 (Supplement 1): 3120.

https://doi.org/10.1182/blood-2024-206700

Published: 2024

Journal Articles

ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53 -Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death

Dongchan Kim, Daehyeon Gwak, Ja Min Byun, Youngil Koh, Junshik Hong, Jung Lim Lee, Sung-Soo Yoon, Dong-Yeop Shin

Blood (2024) 144 (Supplement 1): 1375.

https://doi.org/10.1182/blood-2024-202733

Published: 2024

Journal Articles

Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon

Seug Yun Yoon, Jong-Ho Won, Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Yunsuk Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 3170.

https://doi.org/10.1182/blood-2024-207042

Published: 2024

Journal Articles

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Blood (2024) 144 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2024-200397

Published: 2024

Journal Articles

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Blood (2024) 144 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2024-207033

Published: 2024

Journal Articles

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Sung-Soo Yoon, Dongyeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yoo Jin Lee, Joseph Clarey, Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2023) 142 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2023-185606

Published: 2023

Journal Articles

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Blood (2023) 142 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2023-190995

Published: 2023

Journal Articles

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

Yang Song, Jin Seok Kim, CS Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Wei-Ying Jen, Xinhua Li, Yogesh Mahadev Pokharkar, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2023-184723

Published: 2023

Journal Articles

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2023) 142 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2023-184431

Published: 2023

Journal Articles

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Swami P. Iyer, Sabarish R. Ayyappan, Irl Brian Greenwell, Won Seog Kim, Seung Tae Lee, Jin Seok Kim, Won-Sik Lee, Youngwoo Jeon, William Johnson, Utpal P. Dave, Sung-Soo Yoon, Ka-Won Kang, Florent Carrette, Julien Viotti, A.J. Leyco, Marianna Muller, Steven M. Horwitz

Blood (2023) 142 (Supplement 1): 3072.

https://doi.org/10.1182/blood-2023-172537

Published: 2023

NARROW

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Spectrum of TP53 Mutation in Hematologic Malignancies

Distinct Factors Influence on Complete Hematological Response Maintenance in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b: From a Phase 2 Study in South Korea

Ropeginterferon in Low-Risk Patients with Polycythemia Vera

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma

Refining Symptom Response Criteria in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53 -Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death

Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only